Halozyme Therapeutics, Inc. (HALO) 当前追踪市盈率 (P/E) 为 24.5, 前瞻市盈率为 8.4. 追踪盈利收益率为 4.09%, 前瞻盈利收益率 11.89%. PEG 0.04 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $5.01.
本页证实的标准:
SharesGrow 综合评分： 84/100 其中 7/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -12.2 | -0.05 | -38.69 | 8.57 | - |
| 2017 | 43.9 | -0.28 | 13.26 | 8.73 | - |
| 2018 | -26.1 | 0.12 | 8.43 | 13.82 | - |
| 2019 | -35.4 | 3.31 | 27.89 | 13.06 | - |
| 2020 | 45.1 | -0.16 | 38.51 | 21.74 | - |
| 2021 | 14.0 | 0.07 | 28.71 | 12.76 | - |
| 2022 | 38.5 | -0.80 | 45.86 | 11.80 | - |
| 2023 | 17.3 | 0.39 | 58.18 | 5.88 | - |
| 2024 | 13.7 | 0.21 | 16.67 | 5.97 | - |
| 2025 | 25.5 | -1.04 | 165.22 | 5.77 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-0.81 | $146.69M | $-103.02M | -70.2% |
| 2017 | $0.45 | $316.61M | $62.97M | 19.9% |
| 2018 | $-0.56 | $151.86M | $-80.33M | -52.9% |
| 2019 | $-0.50 | $195.99M | $-72.24M | -36.9% |
| 2020 | $0.91 | $267.59M | $129.09M | 48.2% |
| 2021 | $2.74 | $443.31M | $402.71M | 90.8% |
| 2022 | $1.44 | $660.12M | $202.13M | 30.6% |
| 2023 | $2.10 | $829.25M | $281.59M | 34% |
| 2024 | $3.43 | $1.02B | $444.09M | 43.7% |
| 2025 | $2.56 | $1.4B | $316.89M | 22.7% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $8.02 | $7.83 – $8.20 | $1.76B | $1.75B – $1.78B | 4 |
| 2027 | $9.85 | $8.83 – $10.36 | $1.98B | $1.91B – $2.04B | 3 |
| 2028 | $10.92 | $10.85 – $10.98 | $2.14B | $2.14B – $2.14B | 2 |
| 2029 | $9.49 | $9.29 – $9.67 | $1.92B | $1.89B – $1.94B | 1 |
| 2030 | $8.57 | $8.39 – $8.72 | $1.77B | $1.75B – $1.8B | 1 |
